Print Page      Close Window     

Investors

SEC Filings

6-K
OBSEVA SA filed this Form 6-K on 03/30/2018
Entire Document
 


LOGO

 

OBE2109 Phase 3 clinical trials (PRIMROSE) in uterine fibroid patients Primary endpoint: Responder-HMB Reduction 2H:19 28 weeks 24 weeks 8–14 weeks 16-OBE2109-008 100% US sites n = 100 n = 100 n = 100 n = 100 n = 100 16-OBE2109-009 70% Europe 30% US sites n = 100 n = 100 n = 100 n = 100 n = 100      24 weeksPlacebo + placebo add-back Placebo + placebo add-back200mg + add-back 100mg +placebo add-back100mg + placebo add-back 24w follow-up Screening100mg+add-back100 mg + add-back 200mg+placebo add-back200 mg + add-back 200mg+add-back200 mg + add-back Placebo + placebo add-back200mg + add-back 100mg +placebo add-back100mg + placebo add-back 24w follow-up Screening100mg+add-back100 mg + add-back 200mg+placebo add-back200 mg + add-back 200mg+add-back200 mg + add-back IND granted in April 2017 Currently recruiting • Aiming at supporting the registration of two regimens of administration